Search research articles
Contact Us
Filters
Showing results (151-160 of 180) with videos related to
Page
of 18
Sort By:
British Journal of Haematology
|
June 28, 2017
Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma
Elena Bernasconi, Eugenio Gaudio, Pascale Lejeune, et al.
Haematologica
|
August 5, 2018
Bromodomain and extra-terminal domain inhibition modulates the expression of pathologically relevant microRNAs in diffuse large B-cell lymphoma
Afua A Mensah, Luciano Cascione, Eugenio Gaudio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 28, 2015
The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs
Michela Boi, Eugenio Gaudio, Paola Bonetti, et al.
British Journal of Haematology
|
November 27, 2023
The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisib
Giulio Sartori, Chiara Tarantelli, Filippo Spriano, et al.
Blood Advances
|
September 4, 2020
Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO2734
Filippo Spriano, Eugenio Gaudio, Luciano Cascione, et al.
ESMO Open
|
October 12, 2018
BET bromodomain inhibitor birabresib in mantle cell lymphoma: in vivo activity and identification of novel combinations to overcome adaptive resistance
Chiara Tarantelli, Elena Bernasconi, Eugenio Gaudio, et al.
Cancer Research Communications
|
April 17, 2023
IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance
Zoë Johnson, Chiara Tarantelli, Elisa Civanelli, et al.
Molecular Cancer Therapeutics
|
February 7, 2024
ADCT-602, a Novel PBD Dimer-containing Antibody-Drug Conjugate for Treating CD22-positive Hematologic Malignancies
Francesca Zammarchi, Karin E Havenith, Nikoleta Sachini, et al.
Haematologica
|
February 9, 2019
The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models
Stuart W Hicks, Chiara Tarantelli, Alan Wilhem, et al.
Blood Advances
|
March 4, 2020
Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models
Chiara Tarantelli, Martin Lange, Eugenio Gaudio, et al.
Page
of 18
Search research articles
Search
Showing results (151-160 of 180) with videos related to
Sort By:
Page
of 18
British Journal of Haematology
|
June 28, 2017
Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma
Elena Bernasconi, Eugenio Gaudio, Pascale Lejeune, et al.
Haematologica
|
August 5, 2018
Bromodomain and extra-terminal domain inhibition modulates the expression of pathologically relevant microRNAs in diffuse large B-cell lymphoma
Afua A Mensah, Luciano Cascione, Eugenio Gaudio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 28, 2015
The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs
Michela Boi, Eugenio Gaudio, Paola Bonetti, et al.
British Journal of Haematology
|
November 27, 2023
The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisib
Giulio Sartori, Chiara Tarantelli, Filippo Spriano, et al.
Blood Advances
|
September 4, 2020
Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO2734
Filippo Spriano, Eugenio Gaudio, Luciano Cascione, et al.
ESMO Open
|
October 12, 2018
BET bromodomain inhibitor birabresib in mantle cell lymphoma: in vivo activity and identification of novel combinations to overcome adaptive resistance
Chiara Tarantelli, Elena Bernasconi, Eugenio Gaudio, et al.
Cancer Research Communications
|
April 17, 2023
IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance
Zoë Johnson, Chiara Tarantelli, Elisa Civanelli, et al.
Molecular Cancer Therapeutics
|
February 7, 2024
ADCT-602, a Novel PBD Dimer-containing Antibody-Drug Conjugate for Treating CD22-positive Hematologic Malignancies
Francesca Zammarchi, Karin E Havenith, Nikoleta Sachini, et al.
Haematologica
|
February 9, 2019
The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models
Stuart W Hicks, Chiara Tarantelli, Alan Wilhem, et al.
Blood Advances
|
March 4, 2020
Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models
Chiara Tarantelli, Martin Lange, Eugenio Gaudio, et al.
Page
of 18